Allena Pharmaceuticals, Inc. (ALNA) Social Stream

Allena Pharmaceuticals, Inc. (ALNA): $0.08

0.00 (3.16%)

POWR Rating

Component Grades








Add ALNA to Watchlist
Sign Up

Featured Post From StockTwits About ALNA

$ALNA I am bullish on this:
-Cash is reasonable now. With 52M at July 2021. Risk of re-dilution is quite low in 2021.
-No competitors and no options currently for Enteric Hyperoxaluria which has a significant morbidity, mortality and cost burden = high market penetration expected.
-Learning from all previous studies, the Co. de-risked the URIROX-2 protocol = the chances are higher than average for success: such as overpowering with up to 200 pts, taking sicker patients, extending the results to 16-24 weeks, lowering to 2 TABs from 3-5x daily, etc.
-The new data from phase 1a/1b in ALLN-346 is all positive and they are smoothly cruising so far through phase 2a.
-Patents are strong and know how of production complex.
*ALLN-346. Phase 2a interim results in Q4 2021.
*Urirox 2. Interim analysis in Q1 2022, BLA submission in Q4 2022.
BioGem, published August 14, 2021

Loading social stream, please wait...

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!